Novo Nordisk spotlights future innovations within diabetes as insulin sales recede

Novo Nordisk has two types of insulin in the works which would finally bring some much-needed innovation to the area, says Novo exec Camilla Sylvest, pointing out that the area has not received enough attention for a while.

Camilla Sylvest, executive vice president for commercial strategy and corporate affairs at Novo Nordisk | Photo: Novo Nordisk / PR

A number of bleak years for pharmaceutical firm Novo Nordisk’s insulin business, particularly in the US, have been replaced by a bright outlook.

”I don’t think there’s enough talk about our existing insulin business. There are plenty of growth opportunities in our GLP-1 business, but we’re not talking enough about the insulin business. When I say this, it’s because we’re sending new innovations to market in coming years,” says Camilla Sylvest, EVP for commercial strategy and corporate affairs at Novo Nordisk.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs